IDH1 and central nervous system cancer: Notably, mutations in IDH1 and IDH2 are common driver mutations in low grade gliomas, a subset of which can progress to grade IV astrocytomas, are distinct from IDH wildtype GBMs, and represent a parallel disease process with likely alternative mechanisms of evolution [72].